相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
Manali Mukherjee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology
Steven L. Taylor et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
J. Mark FitzGerald et al.
LANCET RESPIRATORY MEDICINE (2018)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
Peter G. Gibson et al.
LANCET (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Katherine N. Cahill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Pathogenesis of asthma: implications for precision medicine
Richard J. Russell et al.
CLINICAL SCIENCE (2017)
The current and future role of biomarkers in type 2 cytokine-mediated asthma management
I. D. Pavord et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2017)
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Mitchell Goldman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Treatable traits: toward precision medicine of chronic airway diseases
Alvar Agusti et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Claus Bachert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study
Ruth A. Hartley et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry
Joan Sweeney et al.
THORAX (2016)
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
Paul M. O'Byrne et al.
LANCET RESPIRATORY MEDICINE (2016)
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
Sherif Gonem et al.
LANCET RESPIRATORY MEDICINE (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk
D. Kaur et al.
ALLERGY (2015)
A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma
Richard M. Nowak et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2015)
D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells
Sally E. Stinson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme
Norbert Krug et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma
David F. Choy et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry
Stephen O'Neill et al.
THORAX (2015)
Type 2 inflammation in asthma - present in most, absent in many
John V. Fahy
NATURE REVIEWS IMMUNOLOGY (2015)
Asthma Therapy and Its Effect on Airway Remodelling
Rachid Berair et al.
DRUGS (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis
Wendy C. Moore et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
Pranabashis Haldar et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan Long et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study)
Joshua Agbetile et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gail M. Gauvreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment Resistant Severe Asthma
Benjamin J. Green et al.
PLOS ONE (2014)
Expression of DP2 (CRTh2), a Prostaglandin D2 Receptor, in Human Mast Cells
Tae Chul Moon et al.
PLOS ONE (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2014)
The effects of thymic stromal lymphopoietin and IL-3 on human eosinophil-basophil lineage commitment: Relevance to atopic sensitization
Claudia C. K. Hui et al.
IMMUNITY INFLAMMATION AND DISEASE (2014)
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
William W. Busse et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study
Nicola A. Hanania et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammation
Merritt L. Fajt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Increased airway smooth muscle in preschool wheezers who have asthma at school age
Ruth O'Reilly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
Guy G. Brusselle et al.
THORAX (2013)
Eosinophils as diagnostic tools in chronic lung disease
Osama Eltboli et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2013)
Increased Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Expression Mediates Intrinsic Airway Smooth Muscle Hypercontractility in Asthma
Amanda Sutcliffe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic
Kelly Wong McGrath et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Lung damage and airway remodelling in severe asthma
C. E. Brightling et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
Aarti Shikotra et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Conroy Wong et al.
LANCET (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Asthma phenotypes: the evolution from clinical to molecular approaches
Sally E. Wenzel
NATURE MEDICINE (2012)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial
S. T. Holgate et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161
Jenny M. Mjosberg et al.
NATURE IMMUNOLOGY (2011)
Azithromycin for Prevention of Exacerbations of COPD
Richard K. Albert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Eosinophils, bronchitis and asthma: Pathogenesis of cough and airflow obstruction
C. E. Brightling
PULMONARY PHARMACOLOGY & THERAPEUTICS (2011)
Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD
Camille Doe et al.
CHEST (2010)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma
Neeta S. Kulkarni et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Relationship between pretreatment specific IgE and the response to omalizumab therapy
U. Wahn et al.
ALLERGY (2009)
A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma
Sally E. Wenzel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma
Prescott G. Woodruff et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Qualitative Analysis of High-Resolution CT Scans in Severe Asthma
Sumit Gupta et al.
CHEST (2009)
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma
B. R. O'Driscoll et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Economic burden of asthma: a systematic review
Katayoun Bahadori et al.
BMC Pulmonary Medicine (2009)
The presence of rhinovirus in lower airways of patients with bronchial asthma
Monika Wos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: Cooperative roles for CADM1, stem cell factor, and IL-6
Fay Hollins et al.
JOURNAL OF IMMUNOLOGY (2008)
The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma:: a double blind, randomised, placebo controlled trial
J. B. Morjaria et al.
THORAX (2008)
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
J. Bousquet et al.
RESPIRATORY MEDICINE (2007)
被撤回的出版物: The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma (Retracted article. See vol. 183, pg. 418, 2011)
Edward M. Erin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The link between fungi and severe asthma: a summary of the evidence
DW Denning et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Evidence of a role of tumor necrosis factor α in refractory asthma
MA Berry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of TH2-attracting chemokines and disease severity
S Ying et al.
JOURNAL OF IMMUNOLOGY (2005)
Asthma as a risk factor for invasive pneumococcal disease
TR Talbot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The global burden of asthma: executive summary of the GINA Dissemination Committee Report
M Masoli et al.
ALLERGY (2004)
Airway structural alterations selectively associated with severe asthma
L Benayoun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway
PT Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids
RH Green et al.
THORAX (2002)
Non-eosinophilic asthma: importance and possible mechanisms
J Douwes et al.
THORAX (2002)
Mast-cell infiltration of airway smooth muscle in asthma
CE Brightling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study
JM Corne et al.
LANCET (2002)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
MJ Leckie et al.
LANCET (2000)
分享论文
